US Food and Drug Administration–approved capmatinib is an effective second-line treatment for patients with MET exon 14–mutated NSCLC.
Ramucirumab plus Erlotinib in the Treatment of Patients with NSCLC with EGFR Exon 19 or Exon 21 Mutations
First-line treatment with ramucirumab plus erlotinib in patients with EGFR-mutated metastatic NSCLC was associated with superior progression-free survival compared with erlotinib plus placebo.
First-Line Treatment with Lorlatinib Improves Outcomes Over Crizotinib in Patients with ALK-Positive NSCLC
Lorlatinib is associated with longer progression-free survival and a higher overall and intracranial response rates among patients with previously untreated, advanced ALK-positive NSCLC.
Pralsetinib and Selpercatinib Evaluated as Treatment for Patients with RET Gene Fusion–Positive NSCLC
Selpercatinib and pralsetinib are US Food and Drug Administration–approved treatment options for patients with RET fusion–positive NSCLC.
Afatinib in Asian and Non-Asian Patients with EGFR Mutation–Positive NSCLC Harboring Uncommon Mutations
Study evaluated the benefits of afatinib in Asian and non-Asian patients who had not received EGFR-TKI therapy for their EGFR-mutant NSCLC.
Patients with untreated advanced NSCLC with EGFR mutations achieved improved progression-free survival with treatment with gefitinib and carboplatin plus pemetrexed compared with gefitinib alone.
Researchers report higher overall response rate, median duration of response, and median progression-free survival in treatment-naïve patients with a MET exon 14 skipping mutation compared with previously treated patients.
Overall response rate, duration of response, and media progression-free survival were highest in the group of treatment-naïve patients with T790M negativity and any MET mutation.
Treatment was well tolerated and also associated with delayed progression in previously treated patients with NSCLC and METAmp/Ex14Δ.
Results 1 - 9 of 9